

PEDIATRIX MEDICAL GROUP, INC.
RECONCILIATION OF INCOME (LOSS) FROM CONTINUING OPERATIONS
TO ADJUSTED EBITDA FROM CONTINUING OPERATIONS ATTRIBUTABLE TO PEDIATRIX MEDICAL GROUP, INC.
(in thousands)
(Unaudited)

	Three Months Ended March 31, 2023	Three Months Ended June 30, 2023	Three Months Ended September 30, 2023	Three Months Ended December 31, 2023	Twelve Months Ended December 31, 2023
Income (loss) from continuing operations attributable to Pediatrix Medical Group, Inc.	\$ 14,206	\$ 28,282	\$ 21,391	\$ (124,287)	\$ (60,408)
Interest expense	10,390	11,230	10,374	10,081	42,075
Income tax provision	6,506	10,665	9,441	(14,563)	12,049
Depreciation and amortization expense	8,953	8,945	9,211	9,062	36,171
Transformational and restructuring related expenses	-	-	-	2,219	2,219
Impairment losses	-	-	-	168,312	168,312
Adjusted EBITDA from continuing operations attributable to Pediatrix Medical Group, Inc	<u>\$ 40,055</u>	<u>\$ 59,122</u>	<u>\$ 50,417</u>	<u>\$ 50,824</u>	<u>\$ 200,418</u>